Therapeutic options in malignant mesothelioma.
No significant advances have been made in the treatment of diffuse malignant mesothelioma in the past 12 months. For fit patients with early disease (stage I), radical surgery remains the best option, but doubt remains concerning optimum adjuvant therapy. A collaborative approach with multicentre trials of standardized treatment protocols is essential if any progress is to be made in the future.
Moreno de la Santa
P
P
University Hospital of Wales, College of Medicine, Cardiff, UK.
Butchart
E G
EG
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008654:Mesothelioma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D009367:Neoplasm Staging; D010166:Palliative Care
D000970:Antineoplastic Agents; D007372:Interferons